Biotechnology and Life Sciences practice group Partner Jennifer O’Farrell, has been published in the upcoming July edition of the European Biopharmaceutical Review.
Jennifer’s article, entitled “Patenting Biosimilars”, discusses how generics companies are able to use a streamlined process which relies upon previous clinical data to obtain marketing approval for biosimilars. This can enable the generics company to be ready to enter the market as soon as the innovator company’s patent protection expires. In an environment which is seeing convergence between the activities of generics and innovator companies, Jennifer also discusses possibilities for clearing the way to market and the possibility of obtaining patent protection for new formulations and uses of biosimilars.
Click here to read the full article.
This article is taken from European Biopharmaceutical Review July 2018, pages 50-53. © Samedan Ltd